Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company says could lead to faster and more complete disease control.

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically ...

The British pharma is adding $500 million, and ADC production capabilities, to a planned Virginia facility. Elsewhere, ...

The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for ...

The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis.

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the ...

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...

Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by ...

A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple ...

The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it ...